Nanjing Iaso Biotechnology Co., Ltd.
Clinical trials sponsored by Nanjing Iaso Biotechnology Co., Ltd., explained in plain language.
-
New hope for tough lupus cases: experimental therapy UB-VV410 enters human testing
Disease control Recruiting nowThis early-stage study tests an experimental drug called UB-VV410 in 21 adults with active lupus (including lupus nephritis) that hasn't improved with standard treatments. The main goals are to check safety, find the best dose, and see early signs of effectiveness. Participants w…
Phase: PHASE1 • Sponsor: Nanjing IASO Biotechnology Co., Ltd. • Aim: Disease control
Last updated May 17, 2026 08:04 UTC
-
New hope for Tough-to-Treat lymphoma: experimental combo trial opens
Disease control Recruiting nowThis early-stage study tests an experimental drug (UB-VV400) alone and with rapamycin in adults with aggressive B-cell lymphoma that has returned or not responded to treatment. About 70 participants will receive the therapy to find the safest dose and check for side effects. The …
Phase: PHASE1 • Sponsor: Nanjing IASO Biotechnology Co., Ltd. • Aim: Disease control
Last updated May 15, 2026 11:55 UTC